Physician profile
Kishore Jayakumar
NPI 1104321942
$3,319.00
in general payments reported to CMS, 2019-2025
18 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $659 · 2024: $1,112 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,152 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,152.01 |
| Education | $166.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $524.86 | 2024-2025 | Nemluvio |
| Leo Pharma INC. | $449.95 | 2023-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $436.80 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $393.05 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $309.51 | 2023-2025 | Zoryve |
| Abbvie INC. | $266.88 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $210.41 | 2023-2025 | Libtayo, Dupixent |
| Incyte Corporation | $144.74 | 2023-2025 | Opzelura |
| Genzyme Corporation | $140.86 | 2023-2025 | |
| Ucb, INC. | $110.16 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $100.91 | 2023-2025 | |
| Amgen INC. | $96.57 | 2024-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.51 | 2023-2025 | Jublia, Arazlo, Siliq |
| Sun Pharmaceutical Industries INC. | $29.91 | 2023-2024 | Absorica Ld, Winlevi |
| Verrica Pharmaceuticals INC. | $21.83 | 2023 | Ycanth |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $19.23 | 2024 | Vtama |
| Pfizer INC. | $18.66 | 2023 | |
| Organon LLC | $9.16 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kishore Jayakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.